A BILL 
To amend title XVIII of the Social Security Act to require 
the Secretary of Health and Human Services to negotiate 
22:03 Aug 13, 2021
H4811
2 
•HR 4811 IH
prices of drugs furnished under the Medicare program, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Medicare Negotiation 
4
and Competitive Licensing Act of 2021’’. 
5
SEC. 2. REQUIRING THE SECRETARY OF HEALTH AND 
6
HUMAN SERVICES TO NEGOTIATE PRICES OF 
7
DRUGS FURNISHED UNDER THE MEDICARE 
8
PROGRAM. 
9
(a) PART D.—Section 1860D–11 of the Social Secu-
10
rity Act (42 U.S.C. 1395w–111) is amended by striking 
11
subsection (i) and inserting the following new subsection: 
12
‘‘(i) NEGOTIATION OF LOWER DRUG PRICES.— 
13
‘‘(1) IN GENERAL.—Notwithstanding any other 
14
provision of law, the Secretary shall, for plan years 
15
beginning on or after the date of the enactment of 
16
this subsection, negotiate with pharmaceutical man-
17
ufacturers the negotiated prices (including discounts, 
18
rebates, and other price concessions) that may be 
19
charged to PDP sponsors and MA organizations 
20
during a negotiated price period (as specified by the 
21
Secretary) for specified covered part D drugs for 
22
such plan year for part D eligible individuals who 
23
22:03 Aug 13, 2021
H4811
3 
•HR 4811 IH
are enrolled under a prescription drug plan or under 
1
an MA–PD plan. 
2
‘‘(2) NEGOTIATION CONSIDERATIONS.— 
3
‘‘(A) 
FACTORS.—In 
negotiating 
such 
4
prices under paragraph (1), the Secretary shall 
5
take into account the following factors: 
6
‘‘(i) The comparative clinical effective-
7
ness and cost effectiveness, when available 
8
from an impartial source, of such drug. 
9
‘‘(ii) The budgetary impact of pro-
10
viding coverage of such drug. 
11
‘‘(iii) The number of similarly effec-
12
tive drugs or alternative treatment regi-
13
mens for each approved use of such drug. 
14
‘‘(iv) The associated financial burden 
15
on patients that utilize such drug. 
16
‘‘(v) The associated unmet patient 
17
need for such drug. 
18
‘‘(vi) The total revenues from global 
19
sales obtained by the manufacturer for 
20
such drug and the associated investment in 
21
research and development of such drug by 
22
the manufacturer. 
23
‘‘(B) ASSESSMENT OF FACTORS.—For pur-
24
poses of assessing the factors described in sub-
25
22:03 Aug 13, 2021
H4811
4 
•HR 4811 IH
paragraph (A) with respect to a covered part D 
1
drug, the Secretary shall, as soon as prac-
2
ticable, establish a value assessment process 
3
consisting of standardized measures for such 
4
factors. With respect to a negotiation that oc-
5
curs before the Secretary establishes such a 
6
process, the Secretary may use such other as-
7
sessments as the Secretary determines appro-
8
priate (such as assessments used with respect 
9
to ascertaining the value of drugs by the Sec-
10
retary of Veterans Affairs, the Patient-Centered 
11
Outcomes Research Institute, the Institute for 
12
Clinical and Economic Review, and other coun-
13
tries). 
14
‘‘(3) SPECIFIED COVERED PART D DRUGS.—In 
15
this subsection, the term ‘specified covered part D 
16
drug’ means, with respect to a negotiated price pe-
17
riod beginning during— 
18
‘‘(A) the first plan year beginning on or 
19
after the date of the enactment of this sub-
20
section, a covered part D drug that is a sole 
21
source 
drug 
(as 
defined 
in 
section 
22
1833(t)(14)(F)(i))— 
23
22:03 Aug 13, 2021
H4811
5 
•HR 4811 IH
‘‘(i) with respect to which gross reve-
1
nues for the preceding plan year were 
2
$100,000,000 or greater; or 
3
‘‘(ii) that contains an active ingredient 
4
that was first approved by the Adminis-
5
trator for Food and Drugs not later than 
6
10 years prior to the beginning of such 
7
first plan year; 
8
‘‘(B) the second plan year beginning on or 
9
after the date of the enactment of this sub-
10
section, a covered part D drug that is a sole 
11
source drug (as so defined) or a biosimilar bio-
12
logical product; 
13
‘‘(C) the third plan year beginning on or 
14
after the date of the enactment of this sub-
15
section, a covered part D drug— 
16
‘‘(i) that is described in subparagraph 
17
(B); or 
18
‘‘(ii) with respect to which, during the 
19
preceding plan year, fewer than 3 manu-
20
facturers (other than the manufacturer of 
21
such drug) marketed a generic version of 
22
such drug; and 
23
‘‘(D) the fourth plan year beginning on or 
24
after the date of the enactment of this sub-
25
22:03 Aug 13, 2021
H4811
6 
•HR 4811 IH
section or a subsequent plan year, a covered 
1
part D drug. 
2
‘‘(4) NEGOTIATED PRICE LIMITATIONS AND FI-
3
NALIZATION.—The negotiated price of each specified 
4
covered part D drug for a negotiated price period— 
5
‘‘(A) may not be less than an amount nec-
6
essary to allow such manufacturer to recoup 
7
such manufacturer’s research and development 
8
costs associated with such drug; 
9
‘‘(B) subject to subparagraph (A), may not 
10
exceed 110 percent of the median price of such 
11
drug for the preceding plan year in the 10 
12
countries of the Organisation for Economic Co-
13
operation and Development with the highest 
14
gross domestic product and with a per capita 
15
income that is not less than half the per capita 
16
income of the United States for such preceding 
17
plan year; and 
18
‘‘(C) shall be finalized not later than 30 
19
days before a PDP sponsor is required to sub-
20
mit information described in subsection (b)(2) 
21
for the first plan year in such negotiated price 
22
period. 
23
‘‘(5) COMPETITIVE LICENSING AUTHORITY.— 
24
22:03 Aug 13, 2021
H4811
7 
•HR 4811 IH
‘‘(A) IN GENERAL.—Notwithstanding any 
1
exclusivity under clause (iii) or (iv) of section 
2
505(j)(5)(F) of the Federal Food, Drug, and 
3
Cosmetic Act, clause (iii) or (iv) of section 
4
505(c)(3)(E) of such Act, section 351(k)(7)(A) 
5
of the Public Health Service Act, or section 
6
527(a) of the Federal Food, Drug, and Cos-
7
metic Act, or by an extension of such exclusivity 
8
under section 505A of such Act or section 505E 
9
of such Act, and any other provision of law that 
10
provides for market exclusivity (or extension of 
11
market exclusivity) with respect to a drug, in 
12
the case that the Secretary is unable to success-
13
fully negotiate an appropriate price for a speci-
14
fied covered part D drug for a negotiated price 
15
period, the Secretary shall authorize the use of 
16
any patent, clinical trial data, or other exclu-
17
sivity granted by the Federal government with 
18
respect to such drug as the Secretary deter-
19
mines appropriate for purposes of manufac-
20
turing such drug for sale under a Federal 
21
health care program, the insurance program 
22
under chapter 89 of title 5, United States Code, 
23
or a group health plan or health insurance cov-
24
erage offered by a health insurance issuer. Any 
25
22:03 Aug 13, 2021
H4811
8 
•HR 4811 IH
entity making use of a competitive license to 
1
use patent, clinical trial data, or other exclu-
2
sivity under this section shall provide to the 
3
manufacturer holding such exclusivity reason-
4
able compensation, as determined by the Sec-
5
retary based on the following factors: 
6
‘‘(i) The risk-adjusted value of any 
7
Federal government subsidies and invest-
8
ments in research and development used to 
9
support the development of such drug. 
10
‘‘(ii) The risk-adjusted value of any 
11
investment made by such manufacturer in 
12
the research and development of such 
13
drug. 
14
‘‘(iii) The impact of the price, includ-
15
ing license compensation payments, on 
16
meeting the medical need of all patients. 
17
‘‘(iv) The relationship between the 
18
price of such drug, including compensation 
19
payments, and the health benefits of such 
20
drug. 
21
‘‘(v) Other relevant factors determined 
22
appropriate by the Secretary to provide 
23
reasonable compensation. 
24
‘‘(B) REASONABLE COMPENSATION.— 
25
22:03 Aug 13, 2021
H4811
9 
•HR 4811 IH
‘‘(i) LIMITATIONS.—Reasonable com-
1
pensation described in subparagraph (A) 
2
with respect to a specified covered out-
3
patient drug and a plan year may not be 
4
made in an amount— 
5
‘‘(I) less than an amount nec-
6
essary to allow such manufacturer to 
7
recoup such manufacturer’s research 
8
and development costs associated with 
9
such drug; and 
10
‘‘(II) subject to subclause (I), 
11
greater than 12 percent of the nego-
12
tiated price set by the Secretary for 
13
such drug and such plan year. 
14
‘‘(ii) RECOVERY.—The manufacturer 
15
described in subparagraph (A) may seek 
16
recovery against the United States in the 
17
United States Court of Federal Claims. 
18
‘‘(C) INTERIM PERIOD.—Until 1 year after 
19
a drug described in subparagraph (A) is ap-
20
proved under section 505(j) of the Federal 
21
Food, Drug, and Cosmetic Act or section 
22
351(k) of the Public Health Service Act and is 
23
provided under license issued by the Secretary 
24
under such subparagraph, PDP plans and MA– 
25
22:03 Aug 13, 2021
H4811
10 
•HR 4811 IH
PD plans shall not pay more for such drug 
1
than 110 percent of the median of the prices 
2
available, during the most recent 12-month pe-
3
riod for which data is available prior to the be-
4
ginning of such negotiated price period, from 
5
the manufacturer to any wholesaler, retailer, 
6
provider, health maintenance organization, non-
7
profit entity, or governmental entity in the ten 
8
Organisation for Economic Cooperation and 
9
Development countries that have the largest 
10
gross domestic product with a per capita in-
11
come that is not less than half the per capita 
12
income of the United States. 
13
‘‘(D) AUTHORIZATION FOR SECRETARY TO 
14
PROCURE DRUGS DIRECTLY.— 
15
‘‘(i) IN
GENERAL.—The Secretary 
16
may procure a drug manufactured pursu-
17
ant to a competitive license under subpara-
18
graph (A) for purposes of this part or pur-
19
suant to a Federal program license under 
20
subparagraph (C)(ii) for purposes of a 
21
Federal program directly from the entity 
22
manufacturing the drug pursuant to such 
23
a license. 
24
22:03 Aug 13, 2021
H4811
11 
•HR 4811 IH
‘‘(ii) CLARIFICATION REGARDING AP-
1
PLICATION
OF
BUY
AMERICAN
ACT.—In 
2
the case where the Secretary procures a 
3
drug under this subparagraph, the provi-
4
sions of chapter 83 of title 41, United 
5
States Code (commonly referred to as the 
6
‘Buy American Act’) shall apply. 
7
‘‘(E) PRIORITY FOR U.S. MANUFACTURERS 
8
IN AUTHORIZING COMPETITIVE LICENSES.—In 
9
authorizing a competitive license under this 
10
paragraph, the Secretary— 
11
‘‘(i) shall give preference to entities 
12
that the Secretary determines have the 
13
highest safety and security standards; and 
14
‘‘(ii) may give priority to entities that 
15
will manufacture such drug in the United 
16
States. 
17
‘‘(6) FDA REVIEW OF LICENSED DRUG APPLI-
18
CATIONS.—The Secretary shall prioritize review of 
19
applications under section 505(j) of the Federal 
20
Food, Drug, and Cosmetic Act for drugs licensed 
21
under paragraph (3)(A). 
22
‘‘(7) PROHIBITION
OF
ANTICOMPETITIVE
BE-
23
HAVIOR.—No drug manufacturer may engage in 
24
anticompetitive behavior with another manufacturer 
25
22:03 Aug 13, 2021
H4811
12 
•HR 4811 IH
that may interfere with the issuance and implemen-
1
tation of a competitive license or run contrary to 
2
public policy. 
3
‘‘(8) REQUIRED
REPORTING.—The Secretary 
4
may require pharmaceutical manufacturers or any 
5
other entity to disclose to the Secretary such infor-
6
mation that the Secretary determines necessary for 
7
purposes of carrying out this subsection. 
8
‘‘(9) CLARIFICATION.—Nothing in this sub-
9
section shall be construed as preventing the sponsor 
10
of a prescription drug plan or an organization offer-
11
ing an MA–PD plan from obtaining a discount or 
12
reduction of the price for a covered part D drug 
13
below the price negotiated by the Secretary. 
14
‘‘(10) PUBLICATION
OF
NEGOTIATED
PRICES 
15
AND CONTRACT TERMS.—The Secretary shall make 
16
available on a public website the price negotiated 
17
under this subsection, and any contract terms asso-
18
ciated with such price, with respect to each specified 
19
covered part D drug.’’. 
20
(b) PART B.— 
21
(1) IN GENERAL.—Section 1842(o) of the So-
22
cial Security Act (42 U.S.C. 1395u(o)) is amended 
23
by adding at the end the following new paragraph: 
24
22:03 Aug 13, 2021
H4811
13 
•HR 4811 IH
‘‘(8)(A) Notwithstanding any preceding provision of 
1
this subsection, in the case of a drug or biological de-
2
scribed in paragraph (1) furnished during a negotiated 
3
price period beginning on or after January 1 of the first 
4
year beginning on or after the date of the enactment of 
5
this paragraph, the amount payable under this part for 
6
such drug or biological shall be equal to the negotiated 
7
price for such drug or biological and period, as established 
8
pursuant to subparagraph (B). 
9
‘‘(B) The provisions of section 1860D–11(i) shall be 
10
applied to the negotiation of a negotiated price for a drug 
11
or biological described in subparagraph (A) and a nego-
12
tiated price period in a similar manner (as determined by 
13
the Secretary) as such provisions apply with respect to the 
14
negotiation of a negotiated price for a specified part D 
15
drug for a negotiated price period under such section.’’. 
16
(2) APPLICATION TO MA.—Section 1852 of the 
17
Social Security Act (42 U.S.C. 1395w–22) is amend-
18
ed by adding at the end the following new sub-
19
section: 
20
‘‘(o) LIMITATION ON REIMBURSEMENT FOR CERTAIN 
21
DRUGS.—In the case of a drug or biological furnished dur-
22
ing a negotiated price period (as defined for purposes of 
23
section 1842(o)(8)) for which payment may be made 
24
under such section, the total reimbursement for such drug 
25
22:03 Aug 13, 2021
H4811
14 
•HR 4811 IH
or biological made by an Medicare Advantage plan may 
1
not exceed the negotiated price for such drug or biological 
2
and period established pursuant to such section.’’. 
3
SEC. 3. IDENTIFICATION OF PRESCRIPTION DRUG PRICE 
4
SPIKES. 
5
(a) DEFINITIONS.—In this section: 
6
(1) APPLICABLE ENTITY.—The term ‘‘applica-
7
ble entity’’ means the holder of an application ap-
8
proved under subsection (c) or (j) of section 505 of 
9
the Federal Food, Drug, and Cosmetic Act (21 
10
U.S.C. 355) or of a license issued under subsection 
11
(a) or (k) of section 351 of the Public Health Serv-
12
ice Act (42 U.S.C. 262) for a drug described in 
13
paragraph (5)(A). 
14
(2) AVERAGE
MANUFACTURER
PRICE.—The 
15
term ‘‘average manufacturer price’’— 
16
(A) has the same meaning given such term 
17
under section 1927(k)(1) of the Social Security 
18
Act (42 U.S.C. 1396r–8(k)(1)); or 
19
(B) with respect to a drug for which there 
20
is no average manufacturer price as so defined, 
21
such term shall mean the wholesale acquisition 
22
cost of the drug. 
23
22:03 Aug 13, 2021
H4811
15 
•HR 4811 IH
(3) COMMERCE.—The term ‘‘commerce’’ has 
1
the meaning given such term in section 4 of the 
2
Federal Trade Commission Act (15 U.S.C. 44). 
3
(4) INSPECTOR GENERAL.—The term ‘‘Inspec-
4
tor General’’ means the Inspector General of the De-
5
partment of Health and Human Services. 
6
(5) PRESCRIPTION DRUG.— 
7
(A) IN GENERAL.—The term ‘‘prescription 
8
drug’’ means any drug (as defined in section 
9
201(g) of the Federal Food, Drug, and Cos-
10
metic Act (21 U.S.C. 321(g))), including a com-
11
bination product whose primary mode of action 
12
is determined under section 503(g) of such Act 
13
(21 U.S.C. 353(g)) to be that of a drug, and 
14
that— 
15
(i) is subject to section 503(b)(1) of 
16
the Federal Food, Drug, and Cosmetic Act 
17
(21 U.S.C. 353(b)(1)); and 
18
(ii) is covered by a Federal health 
19
care program (as defined in section 
20
1128B(f) of the Social Security Act (42 
21
U.S.C. 1320a–7b(f))). 
22
(B) 
TREATMENT
OF
REFORMULATED 
23
DRUGS.—For purposes of this section, a pre-
24
scription drug with respect to which the Sec-
25
22:03 Aug 13, 2021
H4811
16 
•HR 4811 IH
retary of Health and Human Services has ap-
1
proved any minor reformulation that does not 
2
produce a meaningful therapeutic benefit, the 
3
drug that was approved prior to any such refor-
4
mulation and the drug with any such reformu-
5
lation shall be considered one prescription drug. 
6
(6) PRICE SPIKE.— 
7
(A) IN GENERAL.—The term ‘‘price spike’’ 
8
means an increase in the average manufacturer 
9
price in commerce of a prescription drug for 
10
which the price spike percentage is equal to or 
11
greater than applicable price increase allowance. 
12
(B) 
PRICE
SPIKE
PERCENTAGE.—The 
13
price spike percentage is the percentage (if any) 
14
by which— 
15
(i) the average manufacturer price of 
16
a prescription drug in commerce for the 
17
calendar year; exceeds 
18
(ii) the average manufacturer price of 
19
such prescription drug in commerce for the 
20
calendar year preceding such year. 
21
(C) APPLICABLE PRICE INCREASE ALLOW-
22
ANCE.—The applicable price increase allowance 
23
for any calendar year is the percentage (round-
24
ed to the nearest one-tenth of 1 percent) by 
25
22:03 Aug 13, 2021
H4811
17 
•HR 4811 IH
which the C–CPI–U (as defined in section 
1
1(f)(6) of the Internal Revenue Code of 1986) 
2
for that year exceeds the C–CPI–U for the pre-
3
ceding calendar year. 
4
(7) PRICE SPIKE REVENUE.— 
5
(A) IN GENERAL.—The price spike revenue 
6
for any calendar year is an amount equal to— 
7
(i) the gross price spike revenue, 
8
minus 
9
(ii) the adjustment amount. 
10
(B) GROSS PRICE SPIKE REVENUE.—The 
11
gross price spike revenue for any calendar year 
12
is an amount equal to the product of— 
13
(i) an amount equal to the difference 
14
between clause (i) of paragraph (6)(B) and 
15
clause (ii) of such paragraph; and 
16
(ii) the total number of units of the 
17
prescription drug which were sold in com-
18
merce in such calendar year. 
19
(C) ADJUSTMENT AMOUNT.—The adjust-
20
ment amount is the amount, if any, of the gross 
21
price spike revenue which the Inspector General 
22
has determined is due solely to an increase in 
23
the cost of the inputs necessary to manufacture 
24
the prescription drug subject to the price spike. 
25
22:03 Aug 13, 2021
H4811
18 
•HR 4811 IH
(b) SUBMISSION BY PHARMACEUTICAL COMPANIES 
1
OF INFORMATION TO INSPECTOR GENERAL.— 
2
(1) IN GENERAL.—For each prescription drug, 
3
the applicable entity shall submit to the Inspector 
4
General a quarterly report that includes the fol-
5
lowing: 
6
(A) For each prescription drug of the ap-
7
plicable entity— 
8
(i) the total number of units of the 
9
prescription drug which were sold in com-
10
merce in the preceding calendar quarter; 
11
(ii) the average and median price per 
12
unit of such prescription drug in commerce 
13
in the preceding calendar quarter, disag-
14
gregated by month; and 
15
(iii) the gross revenues from sales of 
16
such prescription drug in commerce in the 
17
preceding calendar quarter. 
18
(B) Such information related to increased 
19
input costs or public health considerations as 
20
the applicable entity may wish the Inspector 
21
General to consider in making a determination 
22
under clause (ii) of subsection (c)(2)(B) or an 
23
assessment in clause (iii) of such subsection for 
24
the preceding calendar quarter. 
25
22:03 Aug 13, 2021
H4811
19 
•HR 4811 IH
(C) Such information related to any antici-
1
pated increased input costs for the subsequent 
2
calendar quarter as the applicable entity may 
3
wish the Inspector General to consider in mak-
4
ing a determination under clause (ii) of sub-
5
section (c)(2)(B) or an assessment in clause 
6
(iii) of such subsection for such calendar quar-
7
ter. 
8
(2) PENALTY FOR FAILURE TO SUBMIT.— 
9
(A) IN GENERAL.—An applicable entity de-
10
scribed in paragraph (1) that fails to submit in-
11
formation to the Inspector General regarding a 
12
prescription drug, as required by such para-
13
graph, before the date specified in paragraph 
14
(3) shall be liable for a civil penalty, as deter-
15
mined under subparagraph (B). 
16
(B) AMOUNT OF PENALTY.—The amount 
17
of the civil penalty shall be equal to the product 
18
of— 
19
(i) an amount, as determined appro-
20
priate by the Inspector General, which is— 
21
(I) not less than 0.5 percent of 
22
the gross revenues from sales of the 
23
prescription drug described in sub-
24
22:03 Aug 13, 2021
H4811
20 
•HR 4811 IH
paragraph (A) for the preceding cal-
1
endar year, and 
2
(II) not greater than 1 percent of 
3
the gross revenues from sales of such 
4
prescription drug for the preceding 
5
calendar year, and 
6
(ii) the number of days in the period 
7
between— 
8
(I) the applicable date specified 
9
in paragraph (3), and 
10
(II) the date on which the In-
11
spector General receives the informa-
12
tion described in paragraph (1) from 
13
the applicable entity. 
14
(3) SUBMISSION DEADLINE.—An applicable en-
15
tity shall submit each quarterly report described in 
16
paragraph (1) not later than January 17, April 18, 
17
June 15, and September 15 of each calendar year. 
18
(c) ASSESSMENT BY INSPECTOR GENERAL.— 
19
(1) IN GENERAL.—Not later than the last day 
20
in February of each year, the Inspector General, in 
21
consultation with other relevant Federal agencies 
22
(including the Federal Trade Commission), shall— 
23
(A) complete an assessment of the infor-
24
mation the Inspector General received pursuant 
25
22:03 Aug 13, 2021
H4811
21 
•HR 4811 IH
to subsection (b)(1) with respect to sales of pre-
1
scription drugs in the preceding calendar year; 
2
and 
3
(B) in the case of any prescription drug 
4
which satisfies the conditions described in para-
5
graph (1) or (2) of subsection (d), submit a rec-
6
ommendation to the Secretary of Health and 
7
Human Services that such drug be exempted 
8
from application of the tax imposed under sec-
9
tion 4192 of the Internal Revenue Code of 1986 
10
(as added by section 3 of this Act) for such 
11
year. 
12
(2) ELEMENTS.—The assessment required by 
13
paragraph (1)(A) shall include the following: 
14
(A) Identification of each price spike relat-
15
ing to a prescription drug in the preceding cal-
16
endar year. 
17
(B) For each price spike identified under 
18
subparagraph (A)— 
19
(i) a determination of the price spike 
20
revenue; 
21
(ii) a determination regarding the ac-
22
curacy of the information submitted by the 
23
applicable entity regarding increased input 
24
costs; and 
25
22:03 Aug 13, 2021
H4811
22 
•HR 4811 IH
(iii) an assessment of the rationale of 
1
the applicable entity for the price spike. 
2
(d) EXEMPTION OF CERTAIN DRUGS.— 
3
(1) IN GENERAL.—The Secretary of Health and 
4
Human Services, upon recommendation of the In-
5
spector General pursuant to subsection (c)(1)(B), 
6
may exempt any prescription drug which has been 
7
subject to a price spike during the preceding cal-
8
endar year from application of the tax imposed 
9
under section 4192 of the Internal Revenue Code of 
10
1986 for such year, if the Secretary determines 
11
that— 
12
(A) based on information submitted pursu-
13
ant to subsection (b)(1)(B), a for-cause price 
14
increase exemption should apply; or 
15
(B)(i) the prescription drug which has 
16
been subject to a price spike has an average 
17
manufacturer price of not greater than $10 for 
18
a 30 day supply; and 
19
(ii) such drug is marketed by not less than 
20
3 other holders of applications approved under 
21
subsection (c) or (j) of section 505 of the Fed-
22
eral Food, Drug, and Cosmetic Act (21 U.S.C. 
23
355), where such applications approved under 
24
22:03 Aug 13, 2021
H4811
23 
•HR 4811 IH
such subsection (j) use as a reference drug the 
1
drug so approved under such subsection (c). 
2
(2) CLARIFICATION.—In considering, under 
3
paragraph (1)(A), information submitted pursuant 
4
to subsection (b)(1)(B), the Secretary— 
5
(A) has the discretion to determine that 
6
such information does not warrant a for-cause 
7
price increase exemption; and 
8
(B) shall exclude from such consideration 
9
any information submitted by the applicable en-
10
tity threatening to curtail or limit production of 
11
the prescription drug if the Secretary does not 
12
grant an exemption from the application of the 
13
tax under section 4192 of the Internal Revenue 
14
Code of 1986. 
15
(e) INSPECTOR GENERAL REPORT
TO INTERNAL 
16
REVENUE SERVICE.— 
17
(1) IN GENERAL.—Subject to paragraph (3), 
18
not later than the last day in February of each year, 
19
the Inspector General shall transmit to the Internal 
20
Revenue Service a report on the findings of the In-
21
spector General with respect to the information the 
22
Inspector General received under subsection (b)(1) 
23
with respect to the preceding calendar year and the 
24
assessment carried out by the Inspector General 
25
22:03 Aug 13, 2021
H4811
24 
•HR 4811 IH
under subsection (c)(1)(A) with respect to such in-
1
formation. 
2
(2) CONTENTS.—The report transmitted under 
3
paragraph (1) shall include the following: 
4
(A) The information received under sub-
5
section (b)(1) with respect to the preceding cal-
6
endar year. 
7
(B) The price spikes identified under sub-
8
paragraph (A) of subsection (c)(2). 
9
(C) The price spike revenue determinations 
10
made under subparagraph (B)(i) of such sub-
11
section. 
12
(D) The determinations and assessments 
13
made under clauses (ii) and (iii) of subpara-
14
graph (B) of such subsection. 
15
(3) NOTICE
AND
OPPORTUNITY
FOR
HEAR-
16
ING.— 
17
(A) IN
GENERAL.—No report shall be 
18
transmitted to the Internal Revenue Service 
19
under paragraph (1) in regards to a prescrip-
20
tion drug unless the Inspector General has pro-
21
vided the applicable entity with— 
22
(i) the assessment of such drug under 
23
subsection (c)(1)(A); and 
24
22:03 Aug 13, 2021
H4811
25 
•HR 4811 IH
(ii) notice of their right to a hearing 
1
in regards to such assessment. 
2
(B) NOTICE.—The notice required under 
3
subparagraph (A) shall be provided to the ap-
4
plicable entity not later than 30 days after com-
5
pletion of the assessment under subsection 
6
(c)(1)(A). 
7
(C) REQUEST FOR HEARING.—Subject to 
8
subparagraph (E), an applicable entity may re-
9
quest a hearing before the Secretary of Health 
10
and Human Services not later than 30 days 
11
after the date on which the notice under sub-
12
paragraph (B) is received. 
13
(D) COMPLETION
OF
HEARING.—In the 
14
case of an applicable entity which requests a 
15
hearing pursuant to subparagraph (C), the Sec-
16
retary of Health and Human Services shall, not 
17
later than 12 months after the date on which 
18
the assessment under subsection (c)(1)(A) was 
19
completed by the Inspector General— 
20
(i) make a final determination in re-
21
gards to the accuracy of such assessment; 
22
and 
23
22:03 Aug 13, 2021
H4811
26 
•HR 4811 IH
(ii) provide the report described in 
1
paragraph (2) to the Internal Revenue 
2
Service. 
3
(E) LIMITATION.—An applicable entity 
4
may request a hearing under subparagraph (C) 
5
with respect to a particular prescription drug 
6
only once within a 5-year period. 
7
(4) PUBLICATION.— 
8
(A) IN GENERAL.—Not later than the last 
9
day in February of each year, subject to sub-
10
paragraph (B), the Inspector General shall 
11
make the report transmitted under paragraph 
12
(1) available to the public, including on the 
13
Internet website of the Inspector General, sub-
14
ject to subparagraph (B). 
15
(B) 
PROPRIETARY
INFORMATION.—The 
16
Inspector General shall ensure that any infor-
17
mation made public in accordance with sub-
18
paragraph (A) excludes trade secrets and con-
19
fidential commercial information. 
20
(f) NOTIFICATION.—The Secretary of the Treasury, 
21
in conjunction with the Inspector General, shall notify, at 
22
such time and in such manner as the Secretary of the 
23
Treasury shall provide, each applicable entity in regard 
24
to any prescription drug which has been determined to 
25
22:03 Aug 13, 2021
H4811
27 
•HR 4811 IH
have been subject to a price spike during the preceding 
1
calendar year and the amount of the tax imposed on such 
2
applicable entity pursuant to section 4192 of the Internal 
3
Revenue Code of 1986. 
4
SEC. 4. EXCISE TAX ON PRESCRIPTION DRUGS SUBJECT TO 
5
PRICE SPIKES. 
6
(a) IN GENERAL.—Subchapter E of chapter 32 of the 
7
Internal Revenue Code of 1986 is amended by adding at 
8
the end the following new section: 
9
‘‘SEC. 4192. PRESCRIPTION DRUGS SUBJECT TO PRICE 
10
SPIKES. 
11
‘‘(a) IMPOSITION OF TAX.— 
12
‘‘(1) IN GENERAL.—Subject to paragraph (3), 
13
for each taxable prescription drug sold by an appli-
14
cable entity during the calendar year, there is hereby 
15
imposed on such entity a tax equal to the greater 
16
of— 
17
‘‘(A) the annual price spike tax for such 
18
prescription drug, or 
19
‘‘(B) subject to paragraph (2), the cumu-
20
lative price spike tax for such prescription drug. 
21
‘‘(2) LIMITATION.—In the case of a taxable 
22
prescription drug for which the applicable period (as 
23
determined under subsection (c)(2)(E)(i)) is less 
24
22:03 Aug 13, 2021
H4811
28 
•HR 4811 IH
than 2 calendar years, the cumulative price spike tax 
1
shall not apply. 
2
‘‘(3) EXEMPTION.—For any calendar year in 
3
which the Secretary of Health and Human Services 
4
has provided an exemption for a taxable prescription 
5
drug pursuant to section 3(d) of the Medicare Nego-
6
tiation and Competitive Licensing Act of 2021, the 
7
amount of the tax determined under paragraph (1) 
8
for such drug or device for such calendar year shall 
9
be reduced to zero. 
10
‘‘(b) ANNUAL PRICE SPIKE TAX.— 
11
‘‘(1) IN GENERAL.—The amount of the annual 
12
price spike tax shall be equal to the applicable per-
13
centage of the price spike revenue received by the 
14
applicable entity on the sale of the taxable prescrip-
15
tion drug during the calendar year. 
16
‘‘(2) APPLICABLE PERCENTAGE.—For purposes 
17
of paragraph (1), the applicable percentage shall be 
18
equal to— 
19
‘‘(A) in the case of a taxable prescription 
20
drug which has been subject to a price spike 
21
percentage greater than the applicable price in-
22
crease 
allowance 
(as 
defined 
in 
section 
23
3(a)(6)(C) of the Medicare Negotiation and 
24
22:03 Aug 13, 2021
H4811
29 
•HR 4811 IH
Competitive Licensing Act of 2021) but less 
1
than 15 percent, 50 percent, 
2
‘‘(B) in the case of a taxable prescription 
3
drug which has been subject to a price spike 
4
percentage equal to or greater than 15 percent 
5
but less than 20 percent, 75 percent, and 
6
‘‘(C) in the case of a taxable prescription 
7
drug which has been subject to a price spike 
8
percentage equal to or greater than 20 percent, 
9
100 percent. 
10
‘‘(c) CUMULATIVE PRICE SPIKE TAX.— 
11
‘‘(1) IN GENERAL.—The amount of the cumu-
12
lative price spike tax shall be equal to the applicable 
13
percentage of the cumulative price spike revenue re-
14
ceived by the applicable entity on the sale of the tax-
15
able prescription drug during the calendar year. 
16
‘‘(2) APPLICABLE PERCENTAGE.— 
17
‘‘(A) IN GENERAL.—For purposes of para-
18
graph (1), the applicable percentage shall be 
19
equal to— 
20
‘‘(i) in the case of a taxable prescrip-
21
tion drug which has been subject to a cu-
22
mulative price spike percentage greater 
23
than the cumulative price increase allow-
24
22:03 Aug 13, 2021
H4811
30 
•HR 4811 IH
ance but less than the first multi-year per-
1
centage, 50 percent, 
2
‘‘(ii) in the case of a taxable prescrip-
3
tion drug which has been subject to a cu-
4
mulative price spike percentage equal to or 
5
greater than the first multi-year percent-
6
age but less than the second multi-year 
7
percentage, 75 percent, and 
8
‘‘(iii) in the case of a taxable prescrip-
9
tion drug which has been subject to a cu-
10
mulative price spike percentage equal to or 
11
greater than the second multi-year percent-
12
age, 100 percent. 
13
‘‘(B) CUMULATIVE PRICE SPIKE PERCENT-
14
AGE.—The cumulative price spike percentage is 
15
the percentage (if any) by which— 
16
‘‘(i) the average manufacturer price of 
17
the taxable prescription drug in commerce 
18
for the preceding calendar year, exceeds 
19
‘‘(ii) the average manufacturer price 
20
of such prescription drug in commerce for 
21
the base year. 
22
‘‘(C) CUMULATIVE
PRICE
INCREASE
AL-
23
LOWANCE.—For purposes of clause (i) of sub-
24
paragraph (A), the cumulative price increase al-
25
22:03 Aug 13, 2021
H4811
31 
•HR 4811 IH
lowance for any calendar year is the percentage 
1
(rounded to the nearest one-tenth of 1 percent) 
2
by which the C–CPI–U (as defined in section 
3
1(f)(6)) for that year exceeds the C–CPI–U for 
4
the base year. 
5
‘‘(D) MULTI-YEAR
PERCENTAGES.—For 
6
purposes of subparagraph (A), the first multi- 
7
year percentage and second multi-year percent-
8
age shall be determined in accordance with the 
9
following table: 
10
‘‘Number of years in applicable period 
First 
multi-year 
percentage 
Second 
multi-year 
percentage 
2 years ....................................................................
17.5 
22.5
3 years ....................................................................
20 
25
4 years ....................................................................
22.5 
27.5
5 years ....................................................................
25 
30. 
‘‘(E) APPLICABLE
PERIOD
AND
BASE 
11
YEAR.— 
12
‘‘(i) APPLICABLE PERIOD.—The appli-
13
cable period shall be the lesser of— 
14
‘‘(I) the 5 preceding calendar 
15
years, 
16
‘‘(II) all calendar years beginning 
17
after the date of enactment of this 
18
section, or 
19
22:03 Aug 13, 2021
H4811
32 
•HR 4811 IH
‘‘(III) all calendar years in which 
1
the taxable prescription drug was sold 
2
in commerce. 
3
‘‘(ii) BASE
YEAR.—The base year 
4
shall be the calendar year immediately pre-
5
ceding the applicable period. 
6
‘‘(3) CUMULATIVE
PRICE
SPIKE
REVENUE.— 
7
For purposes of paragraph (1), the cumulative price 
8
spike revenue for any taxable prescription drug shall 
9
be an amount equal to— 
10
‘‘(A) an amount equal to the product of— 
11
‘‘(i) an amount (not less than zero) 
12
equal to— 
13
‘‘(I) the average manufacturer 
14
price of such prescription drug in 
15
commerce for the preceding calendar 
16
year, minus 
17
‘‘(II) the average manufacturer 
18
price of such prescription drug in 
19
commerce for the base year, and 
20
‘‘(ii) the total number of units of such 
21
prescription drug which were sold in com-
22
merce in the preceding calendar year, 
23
minus 
24
22:03 Aug 13, 2021
H4811
33 
•HR 4811 IH
‘‘(B) an amount equal to the sum of the 
1
adjustment amounts, if any, determined under 
2
section 3(a)(7)(C) of the Medicare Negotiation 
3
and Competitive Licensing Act of 2021 for each 
4
calendar year during the applicable period. 
5
‘‘(d) DEFINITIONS.—For purposes of this section— 
6
‘‘(1) 
TAXABLE
PRESCRIPTION
DRUG.—The 
7
term ‘taxable prescription drug’ means a prescrip-
8
tion drug which has been identified by the Inspector 
9
General of the Department of Health and Human 
10
Services as being subject to a price spike. 
11
‘‘(2) OTHER TERMS.—The terms ‘applicable en-
12
tity’, ‘average manufacturer price’, ‘price spike’, 
13
‘price spike percentage’, and ‘price spike revenue’ 
14
have the same meaning given such terms under sec-
15
tion 3(a) of the Medicare Negotiation and Competi-
16
tive Licensing Act of 2021.’’. 
17
(b) CLERICAL AMENDMENTS.— 
18
(1) The heading of subchapter E of chapter 32 
19
of the Internal Revenue Code of 1986 is amended by 
20
striking ‘‘Medical Devices’’ and inserting ‘‘Cer-
21
tain Medical Devices and Prescription 
22
Drugs’’. 
23
(2) The table of subchapters for chapter 32 of 
24
such Code is amended by striking the item relating 
25
22:03 Aug 13, 2021
H4811
34 
•HR 4811 IH
to subchapter E and inserting the following new 
1
item: 
2
‘‘SUBCHAPTER E. CERTAIN MEDICAL DEVICES AND PRESCRIPTION DRUGS’’. 
(3) The table of sections for subchapter E of 
3
chapter 32 of such Code is amended by adding at 
4
the end the following new item: 
5
‘‘Sec. 4192. Prescription drugs subject to price spikes.’’. 
(c) EFFECTIVE DATE.—The amendments made by 
6
this section shall apply to sales after the date of the enact-
7
ment of this Act. 
8
SEC. 5. APPLICATION OF MEDICARE PRICES TO OTHER IN-
9
SURERS AND THE UNINSURED. 
10
(a) FEDERAL HEALTH CARE PROGRAMS.—Part A of 
11
title XI of the Social Security Act (42 U.S.C. 1301 et seq.) 
12
is amended by adding at the end the following new section: 
13
‘‘SEC. 1150C. APPLICATION OF MEDICARE NEGOTIATED 
14
PRICES. 
15
‘‘(a) IN GENERAL.—Notwithstanding any other pro-
16
vision of law, the price recognized under a Federal health 
17
care program (as defined in section 1128B) or the insur-
18
ance program established under chapter 89 of title 5, 
19
United States Code, for a specified covered part D drug 
20
(as defined in section 1860D–11(i)), or a drug or biologi-
21
cal for which payment may be made under section 
22
1842(o), with respect to a year for which coverage is pro-
23
vided under such Federal health care program or such in-
24
22:03 Aug 13, 2021
H4811
35 
•HR 4811 IH
surance program may not exceed the price for such drug 
1
established under such section 1860D–11(i) or 1842(o), 
2
as applicable. 
3
‘‘(b) APPLICATION
OF OTHER PROVISIONS.—The 
4
provisions of section 1860D–11(i) shall apply with respect 
5
to a Federal health care program and the insurance pro-
6
gram established under chapter 89 of title 5, United 
7
States Code, in the same manner as such provisions apply 
8
with respect to a prescription drug plan or an MA–PD 
9
plan under part D or C, respectively, of title XVIII.’’. 
10
(b) PRIVATE INSURER.—Subpart II of part A of title 
11
XXVII of the Public Health Service Act (42 U.S.C. 
12
300gg–11 et seq.) is amended by adding at the end the 
13
following new section: 
14
‘‘SEC. 2730. APPLICATION OF MEDICARE NEGOTIATED 
15
PRICES. 
16
‘‘(a) IN GENERAL.—Notwithstanding any other pro-
17
vision of law, the price recognized under a group health 
18
plan, or under individual or group health insurance cov-
19
erage offered by a health insurance issuer, for a specified 
20
covered part D drug (as defined in section 1860D–11(i)), 
21
or a drug or biological for which payment may be made 
22
under section 1842(o), with respect to a year for which 
23
coverage is provided under such plan or such coverage may 
24
22:03 Aug 13, 2021
H4811
36 
•HR 4811 IH
not exceed the price for such drug established under such 
1
section 1860D–11(i) or 1842(o), as applicable. 
2
‘‘(b) APPLICATION
OF OTHER PROVISIONS.—The 
3
provisions of section 1860D–11(i) shall apply with respect 
4
to a group health plan, or individual or group health insur-
5
ance coverage offered by a health insurance issuer, in the 
6
same manner as such provisions apply with respect to a 
7
prescription drug plan or an MA–PD plan under part D 
8
or C, respectively, of title XVIII.’’. 
9
(c) UNINSURED.— 
10
(1) IN GENERAL.—Notwithstanding any other 
11
provision of law, the amount that a pharmacy fur-
12
nishing a drug to a specified individual (as defined 
13
in paragraph (2)) may require as payment for such 
14
drug from such individual shall not exceed the price 
15
for such drug established under section 1860D–11(i) 
16
of the Social Security Act (42 U.S.C. 1395w–111(i)) 
17
(or, if applicable, under section 1842(o)(8) of such 
18
Act). 
19
(2) DEFINITION.—For purposes of paragraph 
20
(1), the term ‘‘specified individual’’ means, with re-
21
spect to a drug, an individual who is not covered, or 
22
who has no coverage with respect to such drug, 
23
under a group health plan or group or individual 
24
health insurance coverage (as such terms are defined 
25
22:03 Aug 13, 2021
H4811
37 
•HR 4811 IH
in section 2791 of the Public Health Service Act (42 
1
U.S.C. 300gg–91)) or under a Federal health care 
2
program (as defined in section 1128B of the Social 
3
Security Act, but including the insurance program 
4
established under chapter 89 of title 5, United 
5
States Code). 
6
(3) ENFORCEMENT.—The Secretary of Health 
7
and Human Services may impose a civil monetary 
8
penalty of not more than $10,000 per day on a 
9
pharmacy for a violation of paragraph (1). 
10
SEC. 6. MANUFACTURER PROVISION OF INFORMATION. 
11
(a) IN GENERAL.—In the case of a manufacturer of 
12
a drug or biological subject to a competitive licensing 
13
agreement under section 1860D–11(i)(5) of the Social Se-
14
curity Act, as added by this Act, such manufacturer shall, 
15
upon request from an entity electing to manufacture such 
16
drug or biological, provide to such entity materials, data, 
17
and information relating to the manufacture or supply of 
18
such drug or biological, including— 
19
(1) cellular clones and hybridoma stocks; 
20
(2) plasmids, plasmid maps, and sequences of 
21
antibody complementarity determining regions; 
22
(3) physicochemical and biophysical character-
23
ization; 
24
(4) growth conditions and protocols; 
25
22:03 Aug 13, 2021
H4811
38 
•HR 4811 IH
(5) attenuation or inactivation protocols; 
1
(6) extraction and purification protocols; 
2
(7) synthetic work-up and schemes; 
3
(8) sufficient quantities of the drug or biologi-
4
cal for testing; 
5
(9) the protocols and methods used for testing 
6
the drug or biological; and 
7
(10) the expected outcomes from those proto-
8
cols. 
9
(b) ENFORCEMENT.—The Secretary of Health and 
10
Human Services may impose a civil monetary penalty on 
11
a manufacturer of not more than $10,000 per day for a 
12
violation of subsection (a). 
13
SEC. 7. APPLICABILITY OF NEGOTIATED PRICE TO PRE-
14
SCRIPTION DRUGS FURNISHED BY THE DE-
15
PARTMENT OF DEFENSE AND THE DEPART-
16
MENT OF VETERANS AFFAIRS. 
17
(a) IN GENERAL.—Section 8126(a) of title 38, 
18
United States Code, is amended— 
19
(1) in paragraph (2), by inserting ‘‘, but may 
20
not exceed the amount of the price negotiated by the 
21
Secretary of Health and Human Services under sec-
22
tion 1860D–11(i) of the Social Security Act (42 
23
U.S.C. 1395w–111(i)) (as amended by the Medicare 
24
Negotiation and Competitive Licensing Act of 2019) 
25
22:03 Aug 13, 2021
H4811
39 
•HR 4811 IH
for a specified covered part D drug (as defined in 
1
such section) (or, if applicable, may not exceed the 
2
amount of the price negotiated by the Secretary of 
3
Health 
and 
Human 
Services 
under 
section 
4
1842(o)(8) of such Act for a drug or biological pay-
5
able under such section) that is a covered drug of 
6
a manufacturer’’ after ‘‘best interests of the Depart-
7
ment or such Federal agencies’’; and 
8
(2) in paragraph (3), by inserting ‘‘or, for a 
9
covered drug of a manufacturer that is a specified 
10
covered part D drug (as defined in section 1860D– 
11
11(i) of the Social Security Act (42 U.S.C. 1395w– 
12
111(i)) (as amended by the Medicare Negotiation 
13
and Competitive Licensing Act of 2019)) or a drug 
14
or biological for which payment may be made under 
15
section 1842(o)(8) of such Act, the price negotiated 
16
by the Secretary of Health and Human Services 
17
under such section 1806D–11(i) or 1842(o)(8) (as 
18
applicable) for the specified covered part D drug or 
19
the drug or biological’’ after ‘‘the price charged 
20
under the Federal Supply Schedule at the time the 
21
drug is procured’’. 
22
(b) DEPARTMENT
OF DEFENSE ELEMENTS
FOR 
23
PURPOSES OF PRICING STANDARDS.—Section 1074g(f) of 
24
title 10, United States Code, is amended— 
25
22:03 Aug 13, 2021
H4811
40 
•HR 4811 IH
(1) in the header, by inserting ‘‘AND NATIONAL 
1
MAIL-ORDER PHARMACY PROGRAM’’ after ‘‘PHAR-
2
MACY PROGRAM’’; 
3
(2) by striking ‘‘the TRICARE retail pharmacy 
4
program shall be treated as an element of the De-
5
partment of Defense’’ and inserting ‘‘the TRICARE 
6
retail pharmacy program and the national mail-order 
7
pharmacy program shall be treated as elements of 
8
the Department of Defense’’; and 
9
(3) by striking ‘‘provided by pharmacies under 
10
the program’’ and inserting ‘‘provided under such 
11
programs’’. 
12
SEC. 8. SPECIFIED COVERED PART D DRUGS EXCISE TAX. 
13
(a) IN GENERAL.—Subchapter E of chapter 32 of the 
14
Internal Revenue Code of 1986 is amended by adding at 
15
the end the following new section: 
16
‘‘SEC. 4193. SPECIFIED COVERED PART D DRUGS. 
17
‘‘(a) IN GENERAL.—There is hereby imposed on the 
18
sale by the manufacturer, producer, or importer of any 
19
specified covered part D drug for a price in excess of the 
20
negotiated price in violation of section 1860D–11(i)(5)(C) 
21
of the Social Security Act during any period described in 
22
such section a tax equal to 100 percent of the price for 
23
which so sold. 
24
22:03 Aug 13, 2021
H4811
41 
•HR 4811 IH
‘‘(b) DEFINITIONS.—The terms ‘specified covered 
1
part D drug’ and ‘negotiated price’ have the meaning such 
2
terms have under section 1860D–11 of the Social Security 
3
Act.’’. 
4
(b) CLERICAL AMENDMENTS.— 
5
(1) The heading of subchapter E of chapter 32 
6
of the Internal Revenue Code of 1986 is amended by 
7
striking 
‘‘Medical 
Devices’’ 
and 
inserting 
8
‘‘Other Medical Products’’. 
9
(2) The table of subchapters for chapter 32 of 
10
such Code is amended by striking the item relating 
11
to subchapter E and inserting the following new 
12
item: 
13
‘‘SUBCHAPTER E. OTHER MEDICAL PRODUCTS’’. 
(3) The table of sections for subchapter E of 
14
chapter 32 of such Code is amended by adding at 
15
the end the following new item: 
16
‘‘Sec. 4193. Specified covered part D drugs.’’. 
(c) EFFECTIVE DATE.—The amendments made by 
17
this section shall apply to sales on or after the date that 
18
is 1 year after the date of the enactment of this Act. 
19
SEC. 9. DRUG MANUFACTURER REPORTING. 
20
Part P of title III of the Public Health Service Act 
21
(42 U.S.C. 280g et seq.) is amended by adding at the end 
22
the following: 
23
22:03 Aug 13, 2021
H4811
42 
•HR 4811 IH
‘‘SEC. 399V–7. DRUG MANUFACTURER REPORTING. 
1
‘‘(a) MANDATORY REPORTING.—A drug manufac-
2
turer shall submit to the Secretary and to Congress an 
3
annual report specifying with respect to the previous cal-
4
endar year (except as provided in subsection (d)(2))— 
5
‘‘(1) the total expenditures of the manufacturer 
6
on— 
7
‘‘(A) domestic and foreign drug research 
8
and development, including an itemized descrip-
9
tion of— 
10
‘‘(i) basic and preclinical research; 
11
‘‘(ii) clinical research, reported sepa-
12
rately for each clinical trial; 
13
‘‘(iii) development of alternative dos-
14
age forms and strengths for the drug mol-
15
ecule or combinations, including the mol-
16
ecule; 
17
‘‘(iv) other drug development activi-
18
ties, such as nonclinical laboratory studies 
19
and record and report maintenance; 
20
‘‘(v) pursuing new or expanded indica-
21
tions for such drug through supplemental 
22
applications under section 505 of the Fed-
23
eral Food, Drug, and Cosmetic Act; 
24
22:03 Aug 13, 2021
H4811
43 
•HR 4811 IH
‘‘(vi) carrying out postmarket require-
1
ments related to such drug, including 
2
under section 505(o)(3) of such Act; 
3
‘‘(vii) carrying out risk evaluation and 
4
mitigation strategies in accordance with 
5
section 505–1 of such Act; and 
6
‘‘(viii) marketing research; 
7
‘‘(B) the acquisition of drug components 
8
and packaging, in total and per unit sold, bro-
9
ken out by source and cost and identifying spe-
10
cific costs that reflect internal transfers within 
11
the manufacturer’s company; 
12
‘‘(C) other acquisitions relating to drugs, 
13
including for the purchase of patents and li-
14
censing or the acquisition of any corporate enti-
15
ty owning any rights to a drug during or after 
16
development of the drug; and 
17
‘‘(D) marketing, advertising, and educating 
18
for the promotion of a drug, including a break-
19
down of amounts aimed at consumers, pre-
20
scribers, managed care organizations, and oth-
21
ers, irrespective of whether a particular drug is 
22
mentioned in the marketing, advertising, or 
23
educating; 
24
22:03 Aug 13, 2021
H4811
44 
•HR 4811 IH
‘‘(2) the gross revenue, net revenue, gross prof-
1
it, and net profit of the manufacturer with respect 
2
to drugs; 
3
‘‘(3) the total number of units of each type of 
4
drug that were sold in interstate commerce; 
5
‘‘(4) pricing information with respect to the sale 
6
of drugs, including— 
7
‘‘(A) wholesale acquisition cost; 
8
‘‘(B) net average price realized by pre-
9
scription drug benefit managers for drugs pro-
10
vided to individuals in the United States, after 
11
accounting for any rebates or other payments 
12
from the manufacturer to the pharmacy benefit 
13
manager and from the pharmacy benefit man-
14
ager to the manufacturer; and 
15
‘‘(C) the net price of each drug, after ac-
16
counting for discounts, rebates, or other finan-
17
cial considerations, charged to purchasers in 
18
each applicable country of the Organisation for 
19
Economic Co-operation and Development; 
20
‘‘(5) any Federal benefits received by the manu-
21
facturer with respect to a drug, including the 
22
amounts and periods of impact for each such ben-
23
efit, including tax credits; Federal grants, including 
24
from the National Institutes of Health, the Depart-
25
22:03 Aug 13, 2021
H4811
45 
•HR 4811 IH
ment of Defense, the Department of Energy, the 
1
Centers for Disease Control and Prevention, or other 
2
Federal departments or agencies; patent applications 
3
that benefitted from such grants; patent extensions; 
4
exclusivity periods; and waivers of fees; 
5
‘‘(6) the percentage of research and develop-
6
ment expenditures described in clauses (i) through 
7
(v) of paragraph (1)(A) that were derived from Fed-
8
eral funds; 
9
‘‘(7) executive compensation for the chief execu-
10
tive officer, chief financial officer, and the 3 other 
11
most highly compensated executive officers, includ-
12
ing bonuses, paid by such manufacturer, and stock 
13
options affiliated with the manufacturer that were 
14
offered to or accrued by such officers; and 
15
‘‘(8) any other information as the Secretary 
16
may require. 
17
‘‘(b) VOLUNTARY SUPPLEMENTAL REPORTING.—A 
18
drug manufacturer may supplement a report under sub-
19
section (a) with any additional information the manufac-
20
turer chooses to provide related to drug pricing decisions, 
21
such as— 
22
‘‘(1) total expenditures on drug research, drug 
23
development, and clinical trials on drugs that failed 
24
22:03 Aug 13, 2021
H4811
46 
•HR 4811 IH
to receive approval by the Food and Drug Adminis-
1
tration; and 
2
‘‘(2) a list of drugs and drug prices of other 
3
manufacturers for purposes of comparison with the 
4
manufacturer’s own drugs and drug prices. 
5
‘‘(c) SPECIAL RULE.—A drug manufacturer shall— 
6
‘‘(1) to the extent possible, disaggregate the in-
7
formation required to be reported by this section by 
8
the particular drug involved; and 
9
‘‘(2) submit all information required to be re-
10
ported by this section with respect to each applicable 
11
drug in a single annual report. 
12
‘‘(d) SUBMISSION OF REPORTS.— 
13
‘‘(1) IN GENERAL.— 
14
‘‘(A) SUBMISSION BY DRUG MANUFACTUR-
15
ERS.—Drug manufacturers shall submit the an-
16
nual reports required under this section to the 
17
Secretary in a usable format, as the Secretary 
18
may require. 
19
‘‘(B) COLLATION BY THE SECRETARY.— 
20
The Secretary shall collate the reports received 
21
as described in subparagraph (A) and submit 
22
such collated reports to Congress, together with 
23
an analysis of the reports by the Secretary that 
24
includes— 
25
22:03 Aug 13, 2021
H4811
47 
•HR 4811 IH
‘‘(i) a summary of data from the re-
1
ports; 
2
‘‘(ii) consideration of factors such as 
3
trends on research and development costs, 
4
Federal benefits, and manufacturer patient 
5
assistance programs; and 
6
‘‘(iii) the relationship between the fac-
7
tors described in clause (ii) and prescrip-
8
tion drug prices. 
9
‘‘(C) PUBLIC
AVAILABILITY.—The Sec-
10
retary shall make the reports submitted by 
11
manufacturers as described in subparagraph 
12
(A) and the collated reports together with the 
13
analysis of the Secretary described in subpara-
14
graph (B) publicly available, including by post-
15
ing such reports to the internet website of the 
16
Department of Health and Human Services, in 
17
a searchable format. 
18
‘‘(2) INITIAL REPORT.— 
19
‘‘(A) IN GENERAL.—A drug manufacturer 
20
shall submit an initial report pursuant to this 
21
section not later than one year after the date of 
22
enactment of this subparagraph (except as pro-
23
vided in subparagraph (B)). 
24
22:03 Aug 13, 2021
H4811
48 
•HR 4811 IH
‘‘(B) 
REPORTING
PERIOD.—Notwith-
1
standing the requirement in subsection (a) that 
2
each report under such subsection be for the 
3
previous calendar year, the initial report of a 
4
drug manufacturer under subsection (a) shall 
5
include, for each drug marketed by the manu-
6
facturer, the information described in para-
7
graphs (1) through (6) of subsection (a) for the 
8
calendar year period beginning with the later 
9
of— 
10
‘‘(i) the calendar year in which the 
11
drug was approved under section 505 of 
12
the Federal Food, Drug, and Cosmetic 
13
Act, was licensed under section 351 of this 
14
Act, or received an exemption under sec-
15
tion 505(i) of the Federal Food, Drug, and 
16
Cosmetic Act or section 351(a)(3) of this 
17
Act; and 
18
‘‘(ii) the calendar year in which the 
19
manufacturer acquired the drug so ap-
20
proved, licensed, or exempted. 
21
‘‘(C) SMALL BUSINESSES.—In the case of 
22
a drug manufacturer that has fewer than 500 
23
employees, the initial report required by in sub-
24
22:03 Aug 13, 2021
H4811
49 
•HR 4811 IH
paragraph (A) shall be submitted by a date de-
1
termined by the Secretary, which shall be— 
2
‘‘(i) not earlier than the deadline de-
3
scribed in subparagraph (A); and 
4
‘‘(ii) not later than the date that is 3 
5
years after the date of enactment of this 
6
clause. 
7
‘‘(e) AUDIT BY THIRD PARTY.—The Secretary shall 
8
select a percentage (to be determined by the Secretary) 
9
of the reports submitted under subsection (a) for a fiscal 
10
year to be audited by an accredited third-party auditor 
11
(to be selected by the Secretary). 
12
‘‘(f) PENALTY
FOR NONCOMPLIANCE.—The Sec-
13
retary shall report to the Office of the Inspector General 
14
any manufacturer’s failure to submit a complete report as 
15
required under this section. Any manufacturer that fails 
16
to submit a complete report required under this section 
17
shall be subject to a civil penalty of up to $200,000 for 
18
each day on which the violation continues. The Secretary 
19
shall collect the civil penalties under this subsection and, 
20
without further appropriation, shall use such funds to sup-
21
port research of the National Institutes of Health. 
22
‘‘(g) DEFINITION.—In this section, the term ‘drug 
23
manufacturer’ means the manufacturer of an approved 
24
drug (including a drug approved under subsection (c) or 
25
22:03 Aug 13, 2021
H4811
50 
•HR 4811 IH
(j) of section 505 of the Federal Food, Drug, and Cos-
1
metic Act and a biological product licensed under sub-
2
section (a) or (k) of section 351 of this Act).’’. 
3
Æ 
22:03 Aug 13, 2021
H4811
